Children younger than 5 years are the only age group in the United States not eligible for COVID-19 vaccination<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, June 2, 2022 (HealthDay News) — Pfizer Inc. said Wednesday that it has asked the U.S. Food and Drug Administration to approve the emergency use of its COVID-19 vaccine in children younger than the age of 5 years.<\/p>\n
The company said in a statement that it has provided the agency with data from a phase 2\/3 trial that included almost 1,700 children who received a third dose of the vaccine when omicron was the dominant variant.<\/p>\n
The trial showed that the vaccine triggers a strong immune response and is safe. A month after the third dose, antibody levels in the children were similar to those seen in 16- to 25-year-olds after two doses, according to the company. At midtrial, the vaccine was 80.3 percent effective in preventing symptomatic COVID-19. The findings<\/a> were released May 23, but they have not yet been peer-reviewed or published in a medical journal.<\/p>\n The children in the trial received three 3-mcg doses, with the first two doses given three weeks apart= and the third dose given at least two months after the second dose. The doses for children ages 6 months to 5 years are smaller than those in older groups. Children ages 5 to 12 years receive two doses of a 10-mcg vaccine, and people 12 years and older are given two doses of a 30-mcg vaccine. Both groups are eligible for booster doses, CNN<\/em> reported.<\/p>\n Children younger than 5 years are the only age group in the United States not eligible for COVID-19 vaccination. In late April, Moderna provided the FDA with trial data on the use of its COVID-19 vaccine in children ages 6 months to 5 years. An FDA panel of vaccine experts is set to meet<\/a> on June 15 to discuss both the Moderna and Pfizer requests for the emergency use of COVID-19 vaccines among these younger children.<\/p>\n